Abstract 505: Incidence of Major Bleeding in a Real-World Population of 57,070 Nonvalvular Atrial Fibrillation Patients Treated With Rivaroxaban
Introduction: Rivaroxaban, a direct factor Xa inhibitor approved in 2011, reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). Phase 3 results from the registration trial showed a major bleeding (MB) rate of 3.6 per 100 person-years. Objective: To evaluate MB incidence among NVAF patients taking rivaroxaban in a post-approval clinical setting. Methods: From January 1, 2013 to June 30, 2016, over 10 million electronic medical records from the Department of Defense Military Health System were queried. A validated MB case-finding algorithm (Cunningham) was used to identify MB-related hospitalizations. Major bleeding incidence, patient characteristics, comorbid conditions, concomitant medications, bleeding management, and fatal bleeds were assessed. Results: Of 57,070 rivaroxaban users with NVAF, 1,914 experienced a MB event, with incidence of 2.60 (95% CI 2.49-2.72) per 100 person-years. Patient characteristics and subgroup bleeding rates are displayed in Table 1. There were 62 patients who experienced fatal bleeding, and the mean (SD) age at time of death was 79.3 (7.6) years. Among those who died, 74.2% had intracranial hemorrhage, 22.6% had gastrointestinal hemorrhage, and 3.2% had bleeding in other sites. Conclusion: The incidence, pattern, and management of MB in rivaroxaban users with NVAF in a large and diverse population were generally consistent with the findings from the registration trial. Fatal bleeding was rare.